CLAIMS

1. Use of a compound that modulates the amount or activity of GIBsPLA2 in the manufacture of a medicament for modulating an immune response in a subject in need thereof.
2. The use of claim 1, wherein the compound is a GIBsPLA2 inhibitor or ligand.
3. The use of claim 1, wherein the medicament induces or stimulates said immune response.
4. The use of claim 2, wherein the GIBsPLA2 inhibitor or ligand is selected from an anti-GIBsPLA2 antibody or a derivative thereof, an inhibitory nucleic acid, a soluble receptor, a peptide, or a small drug.
5. The use of claim 4, wherein the GIBsPLA2 inhibitor or ligand is selected from anti-GIBsPLA2 polyclonal antibodies, monoclonal antibodies, fragments thereof selected from F(ab')2 and Fab fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (VHHs or Nanobodies), bivalent antibody fragments (diabodies), as well as recombinantly and synthetically produced binding partners, human antibodies or humanized antibodies or fragments therof.
6. The use of any one of claims 1 to 5, for inducing or stimulating CD4 T cells in the subject.
7. The use of any one of claims 1 to 6, wherein the subject is immuno-deficient or immuno-depressed.
8. The use of any one of claims 1 to 6, wherein the subject has an infectious disease.
9. The use of claim 8, wherein the subject has a viral infection.
10. The use of any one of the preceding claims, for treating AIDS in a HIV-infected subject.
11. The use of claim 10, to suppress or reverse HIV-mediated immunodeficiency.
12. The use of any one of claims 1 to 6, wherein the subject has a cancer.
13. The use of claim 1, wherein the compound is a GIBsPLA2 agonist or activator and said compound decreases an immune response.

14. The use of claim 13, wherein the GIBsPLA2 agonist or activator is a GIBsPLA2 protein or a fragment thereof.
15. The use of claims 13 or 14, wherein the subject has a disease caused by a pathologic or abnormal immune response, preferably selected from an autoimmune disorder, an inflammatory disease, a cancer, an urticaria, an eczema, an allergy, or asthma.
16. The use of any one of claims 1 or 13-15, for reducing graft rejection or reducing GVHD in a subject.
17. The use of any one of the preceding claims, wherein the medicament is to be administered by injection, preferably intramuscular, subcutaneous, transdermal, intraveinous or intraarterial; by nasal, oral, mucosal,rectal administration or by inhalation.
18. A pharmaceutical composition comprising a GIBsPLA2 modulator and a pharmaceutically acceptable carrier or excipient.
19. Use of an immunogen that induces an anti-GIBsPLA2 immune response in the manufacture of a medicament, for modulating the immune system in a subject in need thereof.
20. The use of claim 19, wherein the immunogen comprises a human or animal GIBsPLA2 protein, protein fragment or peptide, or an antigenic fragment or mimotope thereof.
21. The use of claim 19 or 20, wherein the immunogen is in free form, polymerized, or chemically or physically modified, and/or linked to a carrier.
22. The use of any one of claims 19-21, wherein the immunogen is combined with an adjuvant.
23. The use of any one of claims 19-22, wherein the immunogen induces neutralizing antibodies.
24. A vaccine composition comprising an immunogen inducing an anti-GIBsPLA2 immune response, a pharmaceutically acceptable carrier or excipient and, optionally, an adjuvant.
25. The composition of claim 24, wherein the immunogen comprises a GIBsPLA2 protein or peptide, or an antigenic fragment or mimotope thereof.

26. The composition of claim 25, wherein the GIBsPLA2 protein or antigenic fragment or mimotope thereof is in free form, polymerized, or chemically or physically modified, or linked to a carrier and, optionally combined with an adjuvant.

27. A method for diagnosing human immunodeficiency associated with T cell alteration, comprising:

(a) providing a sample containing body fluid or a tissue fragment or cells from a subject, and

(b) detecting or quantifying GIBsPLA2 in the sample.

28. A recombinant cell, wherein said cell or an ancestor thereof has been modified to contain a nucleic acid encoding a GIBsPLA2.

29. A method for producing GIBsPLA2, comprising cultivating a cell of claim 28 under conditions allowing expression of GIBsPLA2, and collecting GIBsPLA2.